In summary, we confirmed a strong synergistic effect between WEE1 inhibitors (WEE1i) and KRAS G12C inhibitors (G12Ci) in KRAS G12C-mutant lung cancer, driven primarily by the MYBL2–RRM2 axis. Here, RRM2 is linked to lung carcinoma.